Agencies
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Agencies | Published : May 9, 2016 4:31 PM IST
The clinical trial included 15 patients who had high levels of the virus in their blood, and 12 other patients whose virus levels were being controlled with antiretroviral therapy (ART). The majority of trial participants were treated at The Rockefeller University Hospital. The patients were infused with a single dose of 3BNC117 and were monitored over a six-month period. The investigators from The Rockefeller University, along with collaborators from the University of Cologne, found that 14 out of 15 patients who had high levels of the virus at the time they were given the antibody were making new antibodies that were able to neutralize a number of different strains of HIV. (Read: HIV diagnosis 5 tests to detect a recent HIV infection)
It usually takes several years for the body to begin to make good antibodies against HIV, Schoofs says. So there might be an even better effect later on, especially if patients are given more than one dose of 3BNC117. The next steps in this research are to test 3BNC117 in combination with other antibodies that target HIV, to determine whether an even stronger antiviral effect can be found. The researchers are also conducting a Phase 2 trial in which patients receiving ART are switched to antibody treatment. The study appears in journal Science. To know more about the factors that increase your risk for HIV, click here
Source: ANI
Photo source: Getty images (Image for representational purpose only)
